477 related articles for article (PubMed ID: 20973534)
1. Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer.
Chattopadhyay N; Cai Z; Pignol JP; Keller B; Lechtman E; Bendayan R; Reilly RM
Mol Pharm; 2010 Dec; 7(6):2194-206. PubMed ID: 20973534
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation.
Chattopadhyay N; Cai Z; Kwon YL; Lechtman E; Pignol JP; Reilly RM
Breast Cancer Res Treat; 2013 Jan; 137(1):81-91. PubMed ID: 23160926
[TBL] [Abstract][Full Text] [Related]
3. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
[TBL] [Abstract][Full Text] [Related]
4. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors.
Germershaus O; Merdan T; Bakowsky U; Behe M; Kissel T
Bioconjug Chem; 2006; 17(5):1190-9. PubMed ID: 16984128
[TBL] [Abstract][Full Text] [Related]
6.
Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
[TBL] [Abstract][Full Text] [Related]
7. Targeted cancer therapy by immunoconjugated gold-gold sulfide nanoparticles using Protein G as a cofactor.
Sun X; Zhang G; Patel D; Stephens D; Gobin AM
Ann Biomed Eng; 2012 Oct; 40(10):2131-9. PubMed ID: 22532323
[TBL] [Abstract][Full Text] [Related]
8. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
[TBL] [Abstract][Full Text] [Related]
9. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.
Mundy DW; Harb W; Jevremovic T
Phys Med Biol; 2006 Mar; 51(6):1377-91. PubMed ID: 16510950
[TBL] [Abstract][Full Text] [Related]
10. Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer.
Her S; Cui L; Bristow RG; Allen C
Radiat Res; 2016 May; 185(5):549-62. PubMed ID: 27135970
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
12. Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles.
Obaid G; Chambrier I; Cook MJ; Russell DA
Photochem Photobiol Sci; 2015 Apr; 14(4):737-47. PubMed ID: 25604735
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analyses of amount and localization of radiosensitizer gold nanoparticles interacting with cancer cells to optimize radiation therapy.
Hatoyama K; Kitamura N; Takano-Kasuya M; Tokunaga M; Oikawa T; Ohta M; Hamada Y; Tada H; Kobayashi Y; Kamei T; Gonda K
Biochem Biophys Res Commun; 2019 Jan; 508(4):1093-1100. PubMed ID: 30551875
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability: a step closer to pharmaceutical approval?
Craig GE; Brown SD; Lamprou DA; Graham D; Wheate NJ
Inorg Chem; 2012 Mar; 51(6):3490-7. PubMed ID: 22390791
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
16. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.
Lesniak D; Xu Y; Deschenes J; Lai R; Thoms J; Murray D; Gosh S; Mackey JR; Sabri S; Abdulkarim B
Cancer Res; 2009 Nov; 69(22):8620-8. PubMed ID: 19887601
[TBL] [Abstract][Full Text] [Related]
17. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.
Biroccio A; D'Angelo C; Jansen B; Gleave ME; Zupi G
J Cell Physiol; 2005 Aug; 204(2):463-9. PubMed ID: 15685647
[TBL] [Abstract][Full Text] [Related]
18. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.
Zhang KX; Kim C; Chow E; Chen IS; Jia W; Rennie PS
Breast Cancer Res Treat; 2011 Jan; 125(1):89-97. PubMed ID: 20232140
[TBL] [Abstract][Full Text] [Related]
19. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
20. PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue.
Eck W; Craig G; Sigdel A; Ritter G; Old LJ; Tang L; Brennan MF; Allen PJ; Mason MD
ACS Nano; 2008 Nov; 2(11):2263-72. PubMed ID: 19206392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
